Ondansetrón B. Braun (Ondansetron)

Ondansetron, the active ingredient in Ondansetrón B. Braun, is a serotonin 5‑HT3 receptor antagonist presented as a tablet for oral use. It is used to prevent nausea and vomiting associated with chemotherapy, radiotherapy and postoperative recovery in adult and paediatric patients.

GNH USA supplies Ondansetrón B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron is employed across several clinical pathways that involve emesis control. - Chemotherapy‑induced nausea and vomiting (CINV): helps reduce the frequency and severity of nausea and vomiting in patients receiving cytotoxic chemotherapy. - Radiotherapy‑induced nausea and vomiting (RINV): provides prophylaxis and treatment of nausea and vomiting caused by radiation therapy. - Post‑operative nausea and vomiting (PONV): reduces the incidence of nausea and vomiting after surgical procedures. - Hyperemesis gravidarum (severe morning sickness): used off‑label in some regions to control persistent vomiting during pregnancy.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Diarrhoea: loose stools, usually transient. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensation. - Injection site pain (if administered intravenously).

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with high intravenous doses. - Severe hypersensitivity: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes in susceptible individuals.

When using Ondansetron, consider the following safety measures: - Cardiac monitoring: assess QT interval in patients with known cardiac disease or electrolyte imbalance. - Drug interactions: review concomitant medications that may prolong QT interval. - Renal impairment: adjust dosing in severe renal dysfunction. - Hepatic impairment: use caution in patients with liver disease. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Ondansetron may interact with several medicines that affect cardiac rhythm or serotonin pathways. Major Interactions (Avoid): - Amiodarone: additive QT‑prolongation risk. - Certain anti‑arrhythmics (e.g., sotalol, quinidine): may cause dangerous cardiac rhythm changes. - Other serotonergic agents (e.g., tramadol, linezolide): increase risk of serotonin syndrome. Moderate Interactions (Monitor Closely): - Antifungal azoles (ketoconazole, fluconazole): can raise ondansetron plasma levels. - Macrolide antibiotics (erythromycin, clarithromycin): may modestly prolong QT interval. - Certain antipsychotics (haloperidol, ziprasidone): require ECG monitoring.